Advertisement
Home Tags Therapy & Procedures: Misc.

Tag: Therapy & Procedures: Misc.

The U.S. Food and Drug Administration emergency approval of blood plasma as a COVID-19 treatment was put on hold last week after senior federal health officials said data supporting the therapy were too weak.

FDA Emergency Approval on Hold for Blood Plasma to Treat COVID-19

0
More data are under review; the approval could still be issued in the near future
Existing evidence on the diagnostic accuracy of serological tests for COVID-19 is characterized by high risks of bias and heterogeneity

Evidence Poor for Accuracy of Serological Tests for COVID-19

0
Evidence for diagnostic accuracy of serological tests characterized by high risks of bias, heterogeneity
Convalescent plasma seems safe for COVID-19 patients based on data from the first 20

Convalescent Plasma Safe for Diverse Patients With COVID-19

0
Incidence of SAEs, including transfusion reactions, thromboembolic or thrombotic events, is low
Pooled data from recent studies show that women with acute stroke are less likely to be treated with intravenous thrombolysis compared with men

Treatment Gap Remains in Stroke Care Between Men and Women

0
Size of this difference has narrowed compared with studies published before 2008
For patients with hip fracture

Pneumonia Risk Down With Nitrogen-Containing Bisphosphonates

0
Reductions in risk for pneumonia and pneumonia mortality seen among patients with hip fracture
The first human trial of an antibody therapy to treat COVID-19 is underway

Human Trial of Antibody Therapy to Treat COVID-19 Underway

0
If drug proves safe and effective, it could be available for use by the fall
Administration of convalescent plasma seems safe and results in improvement in clinical status for patients with severe or life-threatening COVID-19

Convalescent Plasma Appears Promising for Severe COVID-19

0
In series of 25 patients, 19 experienced improvement in clinical status by day 14; 11 were discharged
Initiation of pulmonary rehabilitation within three months of hospital discharge for chronic obstructive pulmonary disease is significantly associated with a lower risk for mortality at one year for Medicare beneficiaries

Pulmonary Rehab Associated With Lower COPD Mortality

0
Only 1.5 percent of patients initiated pulmonary rehabilitation within 90 days of discharge
Use of sodium-glucose cotransporter 2 inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors

SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events

0
Data from three countries showed drop in serious renal events with sodium-glucose cotransporter 2 inhibitors
For adult emergency department patients with syncope

NT-proBNP Does Not Improve Evaluation of Syncope in the ED

0
Serum NT-proBNP concentrations were generally higher in patients with 30-day serious adverse events